Ten years of anti-vascular endothelial growth factor therapy

By N. Ferrara, A. Adamis. Nature reviews. Drug discovery, 2016

953 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation (2017, background): “Notwithstanding the favorable effects of these inhibitors in some patients, they improve progression-free survival and quality of life, but are unfortunately short-lived and modestly influence overall survival in most patients (12, 15, 16).”
VEGF in Signaling and Disease: Beyond Discovery and Development (2019, methodology): “Subsequent clinical studies confirmed the benefits of bevacizumab in colorectal cancer and extended them to additional malignancies, including non-squamous non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), glioblastoma multiforme, ovarian cancer, and cervical cancer, resulting, as o”
Functional morphology of the blood-brain barrier in health and disease (2018, neutral): “Angiogenic signalling and vascular integrity in gliomas VEGF promotes neovessel formation in conjunction with EC-derived Ang-2 [39, 50, 101, 106].”